RESEARCH TRIANGLE PARK, N.C., and TUCSON, Ariz. (Oct. 8, 2013) — Quintiles and the Muscular Dystrophy Association (MDA) today announced a new partnership to develop and implement the U.S. Neuromuscular Disease Registry, a patient registry that will play an important role in determining effective treatments for people with muscular dystrophy and related muscle diseases.
“We are making remarkable progress in researching new lifesaving treatments and cures for neuromuscular diseases as we move from bench to bedside in clinical trials,” said MDA Executive Vice President & Chief Medical and Scientific Officer Valerie Cwik, M.D. “We are committed to changing and saving the lives of the individuals and families we serve, and the U.S. Neuromuscular Disease Registry brings us one step closer to answering critical clinical and research questions that will improve quality of care.”
Quintiles was awarded the project based on its depth of experience in post-marketing research, multistakeholder strategy, and systems-oriented approach to registry design and development.
“Patient registries are an increasingly important component of real-world evidence development for understanding the cause of disease and identifying effective treatments,” said Richard Gliklich, M.D., president of Quintiles Outcome, the real-world and late phase division of Quintiles. “In designing the U.S. Neuromuscular Disease Registry, our goal is to create a research and collaboration platform that will enable physicians, patients, caregivers and others involved in MDA’s mission to collaborate to advance new treatments for patients.”
MDA will use the registry to study the natural history of muscular dystrophy and related muscle diseases, collect information on practice patterns, inform care guidelines and improve quality of care for patients. The registry is currently available at 25 medical clinics within the organization’s national network, with plans to expand to their full network of 200 clinics by 2015. It will gather data in a common format across neuromuscular diseases, starting with amyotrophic lateral sclerosis (ALS), Becker muscular dystrophy/Duchene muscular dystrophy (BMD/DMD) and spinal muscular atrophy (SMA), with plans to collect data on three other neuromuscular diseases within the next three years.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex health care environment as they seek to improve efficiency and effectiveness in the delivery of better health care outcomes.
The Muscular Dystrophy Association is the world’s leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement. Visit mda.org and follow us at facebook.com/MDAnational and @MDAnews.
Muscular Dystrophy Association — USA
222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2014, Muscular Dystrophy Association Inc. All rights reserved.